Market Place
Sourcing Support
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
04 Dec 2024 //
PHARMAPHORUM
Ipsen taps Biomunex`s MAITs to treat solid tumors in $610M bet
03 Dec 2024 //
FIERCE BIOTECH
Ipsen, Biomunex Partner For MAIT Cell Engager In Immuno-Oncology
02 Dec 2024 //
GLOBENEWSWIRE
Bylvay® Data Shows Improvement In Severe Itch & Serum Bile Acids
18 Nov 2024 //
GLOBENEWSWIRE
Iqirvo Data Shows Long Efficacy in PBC with Fatigue Improvement
15 Nov 2024 //
GLOBENEWSWIRE
GENFIT Announces Updates & Participation at Liver Meeting® 2024
13 Nov 2024 //
GLOBENEWSWIRE
Ipsen Monthly Info on Voting Rights & Share Capital (Oct 2024)
07 Nov 2024 //
GLOBENEWSWIRE
Ipsen Delivers Strong Sales Momentum And Raises Guidance
23 Oct 2024 //
GLOBENEWSWIRE
Ipsen receives its second Shingo Prize for operational excellence
14 Oct 2024 //
GLOBENEWSWIRE
UK MHRA Grants Approval For Ipsen’s Elafibranor Treatment
10 Oct 2024 //
PHARMABIZ
Ipsen - September 2024 - Monthly Information On Voting Rights
09 Oct 2024 //
GLOBENEWSWIRE
Ipsen`s IQIRVO Approval Intensifies Primary Biliary Cholangitis
02 Oct 2024 //
PR NEWSWIRE
Ipsen picks up EU approvals for rare disease meds Kayfanda
24 Sep 2024 //
GLOBENEWSWIRE
Ipsen`s Kayfanda Approved In EU For Alagille Syndrome Pruritus
23 Sep 2024 //
GLOBENEWSWIRE
EU Approves Ipsen`s Iqirvo For Biliary Cholangitis
20 Sep 2024 //
GLOBENEWSWIRE
Ipsen Pharma`s Iqirvo (elafibranor) Receives Approval in Europe
19 Sep 2024 //
EMA
Ipsen Pharma`s Kayfanda (odevixibat) Receives Approval in Europe
19 Sep 2024 //
EMA
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Cabometyx Efficacy In Neuroendocrine Tumors Reinforced
16 Sep 2024 //
GLOBENEWSWIRE
Ipsen Updates On CONTACT-02 Trial In Prostate Cancer After Final Analysis
15 Sep 2024 //
GLOBENEWSWIRE
Demy-Colton`s BioFuture 2024 To Feature Regeneron, IBM, Ipsen, And VCs
11 Sep 2024 //
BUSINESSWIRE
Employee of French drugmaker Ipsen to plead guilty to US insider trading
10 Sep 2024 //
REUTERS
Ipsen Reports August 2024 Voting Rights And Share Capital
04 Sep 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
13 Aug 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
06 Aug 2024 //
GLOBENEWSWIRE
Ipsen Reports July 2024 Voting Rights And Share Capital Information
05 Aug 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
30 Jul 2024 //
GLOBENEWSWIRE
CHMP Endorses New Medicines From Astellas, J&J And Ipsen
26 Jul 2024 //
FIERCE PHARMA
Ipsen Gets CHMP Nod For Iqirvo And Kayfanda In Rare Liver Diseases
26 Jul 2024 //
GLOBENEWSWIRE
Ipsen And Day One Partner On Tovorafenib For Childhood Brain Tumor
25 Jul 2024 //
GLOBENEWSWIRE
Ipsen Reports Strong H1 2024 Results, Upgrades Full-Year Guidance
25 Jul 2024 //
GLOBENEWSWIRE
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
25 Jul 2024 //
GLOBENEWSWIRE
Ipsen Secures Ex-US Rights To Day One`s Pediatric Cancer Med For $111M
25 Jul 2024 //
FIERCE PHARMA
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
23 Jul 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
16 Jul 2024 //
GLOBENEWSWIRE
Ipsen scores 2nd ADC via $1B biobucks pact with Foreseen
12 Jul 2024 //
PRESS RELEASE
Ipsen And Foreseen Biotech Sign Global License For Novel ADC
11 Jul 2024 //
GLOBENEWSWIRE
Ipsen scores 2nd preclinical ADC via $1B biobucks pact with Foreseen
11 Jul 2024 //
FIERCE BIOTECH
Ipsen Reports June 2024 Voting Rights And Share Capital Information
09 Jul 2024 //
GLOBENEWSWIRE
Half-year statement of IPSEN liquidity agreement - 2024 06 30
08 Jul 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
02 Jul 2024 //
GLOBENEWSWIRE
Ipsen Expands Cabometyx Collaboration For Neuroendocrine Tumors
02 Jul 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
25 Jun 2024 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
11 Jun 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug
11 Jun 2024 //
REUTERS
Ipsen`s Iqirvo Receives Accelerated FDA Approval For Cholangitis Treatment
10 Jun 2024 //
GLOBENEWSWIRE
Ipsen, Marengo ink $1.2B biobuck deal to treat cold tumors
08 Jun 2024 //
FIERCE BIOTECH
Ipsen, Marengo Partner On Tri-STAR Precision T-Cell Engagers
07 Jun 2024 //
GLOBENEWSWIRE
Ipsen Shares Monthly Voting Rights And Share Capital Information
06 Jun 2024 //
GLOBENEWSWIRE
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
06 Jun 2024 //
GLOBENEWSWIRE
Gilead, Ipsen build the case for their PBC drugs at EASL
05 Jun 2024 //
PHARMAPHORUM
Ipsen: Long-Term Elafibranor Efficacy & QoL In PBC Patients
05 Jun 2024 //
GLOBENEWSWIRE
Ipsen Initiates Share Buyback For Employee Stock Plan
03 Jun 2024 //
GLOBENEWSWIRE
Ipsen announces the launch of an employee shareholding plan
30 May 2024 //
GLOBENEWSWIRE
Annual General Meeting of Ipsen S.A. held on 28 May 2024
28 May 2024 //
GLOBENEWSWIRE
Ipsen Share Buyback Framework: For Agm Shareholder Approval Detailed
28 May 2024 //
GLOBENEWSWIRE
FDA denies Ipsen`s citizen petition for blockbuster drug Somatuline
24 May 2024 //
ENDPTS
Ipsen Preps For 2024 Annual General Meeting Document Availability
07 May 2024 //
GLOBENEWSWIRE
Ipsen Shares, Voting Rights Composition Monthly Update
06 May 2024 //
GLOBENEWSWIRE
Ipsen appoints Keira Driansky as EVP, President of North America
02 May 2024 //
GLOBENEWSWIRE
